Advertisement

Topics

Kite Files the Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel

11:39 EDT 8 Aug 2017 | Biotech-Finances

Monday, July 31st 2017 at 12:30pm UTC Submission Based on Primary Analysis of ZUMA-1 in Patients with Aggressive NHL Accelerated Assessment Granted Through Priority Medicines (PRIME) Regulatory Initiative SANTA MONICA, Calif.–(BUSINESS WIRE)– Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, today announced that it has submitted a Marketing Authorization Application (MAA) to the European …

Cet article Kite Files the Industry’s First CAR-T Marketing Authorization
Application in Europe for Axicabtagene Ciloleucel
est apparu en premier sur EEI-BIOTECHFINANCES.

Original Article: Kite Files the Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel

NEXT ARTICLE

More From BioPortfolio on "Kite Files the Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel"

Quick Search
Advertisement